European Section & Committees

ARM's European Section comprises companies, institutions, non-profit groups and Europe-based national organizations dedicated to advancing regenerative medicine and other advanced therapy products.

The section serves as a focal point for industry efforts to work with the European Medicines Agency (EMA), its Committee for Advanced Therapies (CAT) and other regulatory authorities to help build a safe, rational and robust framework for the approval of advanced therapy medicinal products (ATMPs).

The section also works to establish and maintain relationships with European investor groups and pharmaceutical companies to further their understanding of the value and potential of these transformative therapies.

Additionally, the section provides a single voice within Europe, delivering coordinated messaging and communication strategies for the sector, conveying the opportunities and challenges in developing successful ATMPs to all major stakeholders.

Michael Hunt, Chief Financial Officer, ReNeuron
Alexander Vos, CEO, PharmaCell
Christian Homsy, CEO, Celyad

ARM's European-Focused Committees:

EU Committee on Regulatory Affairs

This committee addresses EU-specific issues and topics related to the regulatory framework of Advanced Therapy Medicinal Product (ATMP) development and manufacture. Its main objectives are two-fold: to contribute consistently and meaningfully to discussions and initiatives to improve the regulatory landscape in the EU, including where appropriate within individual member states and to highlight the regulatory challenges and hurdles experienced by ARM member organizations to the relevant public authorities (EU-level and, where appropriate, nationally). Advocate for practical solutions to facilitate product development and patient access to innovative treatments.
This committee is open to participation from all ARM members.

EU Committee on Reimbursement
This group addresses EU-specific issues and topics related to pricing, reimbursement and market access of Advanced Therapy Medicinal Products (ATMPs). Its main objectives are as follows: To establish ARM a resource for our members regarding pricing & reimbursement (P&R) and market access systems and how they work and to help shape the discussions on P&R and market access for ATMPs
This committee is open to participation from all ARM members. 

For questions about the above committees, or to join, please contact Drew Gorman